|
|
- MHRA (Medicines) Drug Alerts (Various Recipients)
- Other contacts
- Independent Healthcare Providers (registered with CAS)
- Clinical Commissioning Groups
- NHS Regional Offices
- NHS Foundation Trusts (England) - Medical Director
- NHS Foundation Trusts (England) - Chief Executive
- Social Care Providers (registered with CAS)
- Special Health Authorities
- NHS Trusts (England) - Medical Director
- CMO Urgent Messages - Non-NHS Recipients on Public Health Link
- MHRA (Medicines) Drug Alerts - Non-NHS Recipients
- Territorial CMOs in Northern Ireland, Scotland & Wales
- Regional Directors of Public Health
- Consultants in Communicable Diseases
- CMO Urgent Messages - Recipients on Public Health Link
- Director of Public Health
- NHS Trusts (England) - Chief Executive
- GP - Locum
- NHS 111 and Out of hours providers
- GP Practices
- DHSC Supply Disruption - Medicines
- Community Pharmacy
- Primary Care Networks
- GP Practices 1
|
| Title: |
|
Influenza season 2022/2023: Use of antiviral medicines
|
| Broadcast content: |
|
UKHSA surveillance data indicates that influenza is circulating in the community.Prescribers working in primary care may now prescribe, and community pharmacists may now supply antiviral medicines (oseltamivir and zanamivir) for the prophylaxis and treatment of influenza at NHS expense. This is in accordance with NICE guidance, and Schedule 2 to the National Health Service (General Medical Services Contracts (Prescription of drugs etc) Regulations 2004), commonly known as the Grey List or Selected List Scheme (SLS).
Antiviral medicines may be prescribed for patients in clinical at-risk groups as well as anyone at risk of severe illness and/or complications from influenza if not treated.
Further information is provided in the attached document from the Chief Medical Officer and Chief Pharmaceutical Officer.
|
| Additional information: |
|
NHS England Regional Offices: please cascade this alert to community pharmacy
|